<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40949724</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1482-1826</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Journal of pharmacy &amp; pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</Title><ISOAbbreviation>J Pharm Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database.</ArticleTitle><Pagination><StartPage>14917</StartPage><MedlinePgn>14917</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14917</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/jpps.2025.14917</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Tiotropium, a long-acting muscarinic antagonist, is commonly employed for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. While its efficacy has been validated through numerous randomized controlled trials, safety concerns in real-world post-marketing settings necessitate further evaluation.</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">This study aimed to analyze the adverse events (AEs) associated with tiotropium reported in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database to identify potential safety signals.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A retrospective analysis was conducted on adverse reaction reports related to tiotropium in the FAERS database from the first quarter of 2004 to the fourth quarter of 2024. The AE names in the FAERS database were systematically classified using the Preferred Terms (PTs) and System Organ Classes (SOCs) provided by the latest version of the Medical Dictionary for Regulatory Activities (MedDRA 27.1). After deduplication, a combination of methods, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS), was employed for disproportionality analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 129,763 AE reports related to tiotropium were included in the analysis, affecting 65,045 patients. These reports encompassed 27 different SOC categories, identifying 264 AEs associated with tiotropium. After excluding certain AEs deemed clinically insignificant, the most common AEs reported were dyspnea (n = 8,600), cough (n = 2,440), and pneumonia (n = 2080). The AEs exhibiting the highest signal strength included aggravated dyspnea (ROR: 162.04), hoarseness (ROR: 43.42), and aggravated chronic obstructive airway disease (ROR: 43.17). Additionally, we identified potential risks not mentioned in the instructions (United States Prescribing Information and the Canadian Product Monograph), such as epiglottic cancer, halo vision, and malignant lung tumors.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study offers a more comprehensive understanding of tiotropium by uncovering previously unreported adverse reactions. Physicians should take these newly identified adverse reactions into account when prescribing this medication.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Rui, Xin, Chen, Xiang, Chen, Zhang and Chen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rui</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Cough, Kunshan Key Laboratory of Chronic Cough, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xin</LastName><ForeName>Tianyuan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Cough, Kunshan Key Laboratory of Chronic Cough, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Cough, Kunshan Key Laboratory of Chronic Cough, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Beiyi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Cough, Kunshan Key Laboratory of Chronic Cough, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Changwen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Cough, Kunshan Key Laboratory of Chronic Cough, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Oncology, Changshu No.1 People's Hospital, Changshu Hospital Affiliated to Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory of Cough, Kunshan Key Laboratory of Chronic Cough, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pharm Pharm Sci</MedlineTA><NlmUniqueID>9807281</NlmUniqueID><ISSNLinking>1482-1826</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>XX112XZP0J</RegistryNumber><NameOfSubstance UI="D000069447">Tiotropium Bromide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000069447" MajorTopicYN="Y">Tiotropium Bromide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="Y">Bronchodilator Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse drug events</Keyword><Keyword MajorTopicYN="N">data mining</Keyword><Keyword MajorTopicYN="N">disproportionality analysis</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">tiotropium</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>13</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>7</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40949724</ArticleId><ArticleId IdType="pmc">PMC12425831</ArticleId><ArticleId IdType="doi">10.3389/jpps.2025.14917</ArticleId><ArticleId IdType="pii">14917</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cao Y, Chen S, Chen X, Zou W, Liu Z, Wu Y, et al. Global trends in the incidence and mortality of asthma from 1990 to 2019: an age-period-cohort analysis using the global burden of disease study 2019. Front Public Health (2022) 10:1036674. 10.3389/fpubh.2022.1036674</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.1036674</ArticleId><ArticleId IdType="pmc">PMC9723391</ArticleId><ArticleId IdType="pubmed">36483262</ArticleId></ArticleIdList></Reference><Reference><Citation>Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis (2014) 5:85&#x2013;98. 10.1177/2040622313518227</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040622313518227</ArticleId><ArticleId IdType="pmc">PMC3926345</ArticleId><ArticleId IdType="pubmed">24587893</ArticleId></ArticleIdList></Reference><Reference><Citation>Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma - a narrative review. Eur J Intern Med (2021) 85:14&#x2013;22. 10.1016/j.ejim.2021.01.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.01.027</ArticleId><ArticleId IdType="pubmed">33563506</ArticleId></ArticleIdList></Reference><Reference><Citation>Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol (2015) 8:479&#x2013;501. 10.1586/17512433.2015.1058154</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/17512433.2015.1058154</ArticleId><ArticleId IdType="pubmed">26109098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 1: saskatchewan cohort study. Chest (2012) 142:298&#x2013;304. 10.1378/chest.10-2499</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.10-2499</ArticleId><ArticleId IdType="pubmed">22871755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest (2012) 142:305&#x2013;11. 10.1378/chest.11-1597</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-1597</ArticleId><ArticleId IdType="pubmed">22871756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesten S, Celli B, Decramer M, Leimer I, Tashkin D. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J chronic obstructive Pulm Dis (2009) 4:397&#x2013;409. 10.2147/copd.s4802</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/copd.s4802</ArticleId><ArticleId IdType="pmc">PMC2793068</ArticleId><ArticleId IdType="pubmed">20037679</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J, Lee JH. Effects of tiotropium on the risk of coronary heart disease in patients with COPD: a nationwide cohort study. Sci Rep (2022) 12:16674. 10.1038/s41598-022-21038-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-21038-1</ArticleId><ArticleId IdType="pmc">PMC9535029</ArticleId><ArticleId IdType="pubmed">36198721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci (2013) 10:796&#x2013;803. 10.7150/ijms.6048</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.6048</ArticleId><ArticleId IdType="pmc">PMC3689877</ArticleId><ArticleId IdType="pubmed">23794943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F, Zhu C, Lou S, Cui Z, Wang D, Ou Y, et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front Pharmacol (2023) 14:1320458. 10.3389/fphar.2023.1320458</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1320458</ArticleId><ArticleId IdType="pmc">PMC10771301</ArticleId><ArticleId IdType="pubmed">38186645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye W, Ding Y, Li M, Tian Z, Wang S, Liu Z. Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database. Front Pharmacol (2024) 15:1452300. 10.3389/fphar.2024.1452300</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2024.1452300</ArticleId><ArticleId IdType="pmc">PMC11424536</ArticleId><ArticleId IdType="pubmed">39329122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z, Shao K, Wang K, Xu M, Yu X, Xu C, et al. Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database. Int J Clin Pharm (2025) 1&#x2013;10. 10.1007/s11096-025-01917-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-025-01917-z</ArticleId><ArticleId IdType="pubmed">40285824</ArticleId></ArticleIdList></Reference><Reference><Citation>Mytheen S, Varghese A, Joy J, Shaji A, Tom AA. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA adverse event reporting system database (FAERS). Expert Opin Drug Saf (2023) 22:985&#x2013;94. 10.1080/14740338.2023.2223955</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2023.2223955</ArticleId><ArticleId IdType="pubmed">37294921</ArticleId></ArticleIdList></Reference><Reference><Citation>Laustsen G, Wimmett L. 2004 drug approval highlights: FDA update. The Nurse Pract (2005) 30:14&#x2013;29. 10.1097/00006205-200502000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006205-200502000-00004</ArticleId><ArticleId IdType="pubmed">15702013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li Y, Zhuang W. Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System. BMC Pharmacol Toxicol (2025) 26:46. 10.1186/s40360-025-00873-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40360-025-00873-8</ArticleId><ArticleId IdType="pmc">PMC11869546</ArticleId><ArticleId IdType="pubmed">40016824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A. The newly available FAERS public dashboard: implications for health care professionals. Hosp Pharm (2019) 54:75&#x2013;7. 10.1177/0018578718795271</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0018578718795271</ArticleId><ArticleId IdType="pmc">PMC6431724</ArticleId><ArticleId IdType="pubmed">30923396</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf (2004) 13:519&#x2013;23. 10.1002/pds.1001</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1001</ArticleId><ArticleId IdType="pubmed">15317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad J, Thurlapati A, Thotamgari S, Grewal US, Sheth AR, Gupta D, et al. Anti-cancer drugs associated atrial fibrillation-an analysis of real-world pharmacovigilance data. Front Cardiovasc Med (2022) 9:739044. 10.3389/fcvm.2022.739044</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.739044</ArticleId><ArticleId IdType="pmc">PMC9051026</ArticleId><ArticleId IdType="pubmed">35498039</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada K, Maruo K, Isogawa N, Yamaguchi Y, Gosho M. Borrowing external information to improve bayesian confidence propagation neural network. Eur J Clin Pharmacol (2020) 76:1311&#x2013;9. 10.1007/s00228-020-02909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-020-02909-w</ArticleId><ArticleId IdType="pubmed">32488331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Ding L, Fu F, Xiao J. Updated insights on dementia-related risk of sacubitril/valsartan: a real-world pharmacovigilance analysis. CNS Neurosci Ther (2023) 29:2548&#x2013;54. 10.1111/cns.14195</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.14195</ArticleId><ArticleId IdType="pmc">PMC10401082</ArticleId><ArticleId IdType="pubmed">36971193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium respimat inhaler and the risk of death in COPD. N Engl J Med (2013) 369:1491&#x2013;501. 10.1056/nejmoa1303342</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1303342</ArticleId><ArticleId IdType="pubmed">23992515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamelmann E, Bateman ED, Vogelberg C, Szefler SJ, Vandewalker M, Moroni-Zentgraf P, et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol (2016) 138:441&#x2013;50.e8. 10.1016/j.jaci.2016.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.01.011</ArticleId><ArticleId IdType="pubmed">26960245</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradding P, Porsbjerg C, C&#xf4;t&#xe9; A, Dahl&#xe9;n S-E, Hallstrand TS, Brightling CE. Airway hyperresponsiveness in asthma: the role of the epithelium. J Allergy Clin Immunol (2024) 153:1181&#x2013;93. 10.1016/j.jaci.2024.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2024.02.011</ArticleId><ArticleId IdType="pubmed">38395082</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi-Hisayoshi Y, Ihara E, Bai X, Tanaka Y, Ogino H, Chinen T, et al. Protective role of M3 muscarinic acetylcholine receptor in indomethacin-induced small intestinal injury. J Mol Med Berl Ger (2024) 102:1175&#x2013;86. 10.1007/s00109-024-02474-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-024-02474-0</ArticleId><ArticleId IdType="pubmed">39172154</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz AA, Grumley S, Yen A, Sonavane S, Elalami R, Abdalla M, et al. Eosinophils, mucus plugs and clinical outcomes: findings from two COPD cohorts. Eur Respir J (2024) 64:2401005. 10.1183/13993003.01005-2024</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01005-2024</ArticleId><ArticleId IdType="pubmed">39572219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettler SK, Nath HP, Grumley S, Orejas JL, Dolliver WR, Nardelli P, et al. Silent airway mucus plugs in COPD and clinical implications. Chest (2024) 166:1010&#x2013;9. 10.1016/j.chest.2023.11.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2023.11.033</ArticleId><ArticleId IdType="pmc">PMC11562650</ArticleId><ArticleId IdType="pubmed">38013161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kistemaker LEM, Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci (2015) 36:164&#x2013;71. 10.1016/j.tips.2014.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2014.11.005</ArticleId><ArticleId IdType="pubmed">25511176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodder R, Pavia D, Dewberry H, Alexander K, Iacono P, Ponitz H, et al. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of respimat soft mist inhaler. Respir Med (2005) 99:1087&#x2013;95. 10.1016/j.rmed.2005.03.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2005.03.037</ArticleId><ArticleId IdType="pubmed">15893465</ArticleId></ArticleIdList></Reference><Reference><Citation>Arslan B, &#xc7;etin GP, Yilmaz &#x130;. The role of long-acting antimuscarinic agents in the treatment of asthma. J Aerosol Med Pulm Drug Deliv (2023) 36:189&#x2013;209. 10.1089/jamp.2022.0059</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jamp.2022.0059</ArticleId><ArticleId IdType="pubmed">37428619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa T, Hashiba K, Cao J, Unno T, Komori S-I, Yamada M, et al. Functional roles of muscarinic M2 and M3 receptors in mouse stomach motility: studies with muscarinic receptor knockout mice. Eur J Pharmacol (2007) 554:212&#x2013;22. 10.1016/j.ejphar.2006.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2006.10.013</ArticleId><ArticleId IdType="pubmed">17113073</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson K-E, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int (2007) 100:1007&#x2013;14. 10.1111/j.1464-410x.2007.07100.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410x.2007.07100.x</ArticleId><ArticleId IdType="pubmed">17922785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ham D, Inoue A, Xu J, Du Y, Chung KY. Molecular mechanism of muscarinic acetylcholine receptor M3 interaction with gq. Commun Biol (2024) 7:362. 10.1038/s42003-024-06056-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-024-06056-1</ArticleId><ArticleId IdType="pmc">PMC10960872</ArticleId><ArticleId IdType="pubmed">38521872</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered janus-activated kinase-STAT3 binding. Cancer Res (2009) 69:1958&#x2013;65. 10.1158/0008-5472.can-08-2944</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.can-08-2944</ArticleId><ArticleId IdType="pmc">PMC2929826</ArticleId><ArticleId IdType="pubmed">19223541</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalobo A. Ca2+ signaling and src functions in tumor cells. Biomolecules (2023) 13:1739. 10.3390/biom13121739</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13121739</ArticleId><ArticleId IdType="pmc">PMC10741856</ArticleId><ArticleId IdType="pubmed">38136610</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res (2007) 13:4233&#x2013;44. 10.1158/1078-0432.ccr-06-2981</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.ccr-06-2981</ArticleId><ArticleId IdType="pubmed">17634553</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, Babkirk K, Chen S, Pei M. Epithelial-to-mesenchymal transition transcription factors: new strategies for mesenchymal tissue regeneration. Cytokine Growth Factor Rev (2025) 83:99&#x2013;124. 10.1016/j.cytogfr.2025.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2025.02.001</ArticleId><ArticleId IdType="pmc">PMC12148707</ArticleId><ArticleId IdType="pubmed">40011185</ArticleId></ArticleIdList></Reference><Reference><Citation>Debnath P, Huirem RS, Dutta P, Palchaudhuri S. Epithelial-mesenchymal transition and its transcription factors. Biosci Rep (2022) 42:BSR20211754. 10.1042/bsr20211754</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bsr20211754</ArticleId><ArticleId IdType="pmc">PMC8703024</ArticleId><ArticleId IdType="pubmed">34708244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci (2007) 80:2314&#x2013;9. 10.1016/j.lfs.2007.02.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2007.02.036</ArticleId><ArticleId IdType="pubmed">17383684</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol (2023) 20:432&#x2013;47. 10.1038/s41423-023-00990-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-00990-6</ArticleId><ArticleId IdType="pmc">PMC10203372</ArticleId><ArticleId IdType="pubmed">36949244</ArticleId></ArticleIdList></Reference><Reference><Citation>Luri-Rey C, Teijeira &#xc1;, Wculek SK, de Andrea C, Herrero C, Lopez-Janeiro A, et al. Cross-priming in cancer immunology and immunotherapy. Nat Rev Cancer (2025) 25:249&#x2013;73. 10.1038/s41568-024-00785-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-024-00785-5</ArticleId><ArticleId IdType="pubmed">39881005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chen Y, Liu Y, Zhao J, Wang G, Chen H, et al. Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-&#x3ba;B and STAT3 signaling pathways in nasopharyngeal carcinoma. Cell Death Dis (2025) 16:129. 10.1038/s41419-025-07444-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-025-07444-z</ArticleId><ArticleId IdType="pmc">PMC11861260</ArticleId><ArticleId IdType="pubmed">40000620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYC, Kennedy BC, Richoz N, Dean I, Tuong ZK, Gaspal F, et al. Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity. Nat Commun (2024) 15:682. 10.1038/s41467-024-44787-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-44787-1</ArticleId><ArticleId IdType="pmc">PMC10808534</ArticleId><ArticleId IdType="pubmed">38267413</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnersley B, Sud A, Everall A, Cornish AJ, Chubb D, Culliford R, et al. Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. Nat Genet (2024) 56:1868&#x2013;77. 10.1038/s41588-024-01785-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-024-01785-9</ArticleId><ArticleId IdType="pmc">PMC11387197</ArticleId><ArticleId IdType="pubmed">38890488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med (2020) 382:41&#x2013;50. 10.1056/nejmoa1913662</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1913662</ArticleId><ArticleId IdType="pubmed">31751012</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer (2010) 126:1630&#x2013;9. 10.1002/ijc.24896</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.24896</ArticleId><ArticleId IdType="pubmed">19795445</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Yu W, Wang L, Zhao M, Guo Q, Lv S, et al. DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis. J Cancer (2017) 8:3585&#x2013;91. 10.7150/jca.21368</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.21368</ArticleId><ArticleId IdType="pmc">PMC5687174</ArticleId><ArticleId IdType="pubmed">29151944</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>